a Adrenomedullin (ADM) correlates with adverse cardiovascular outcomes in patients with acute myocardial infarction (AMI) and in patients with heart failure. Measurement of human mature ADM (mADM) has been difficult, and recent studies have used its surrogate -the mid-regional pro-ADM (MRproADM). Our objective was to determine whether mADM measured by a novel sandwich immunoassay, using the anti-C-terminal and an anti-midregional monoclonal antibody, was prognostic of 30-day, 90-day, 1-year, and 2-year major adverse cardiovascular events (MACEs) in 1111 consecutive patients who have suffered an AMI. We also compared it with the effect of MRproADM in the same patient population. A total of 311 (27.0%) patients experienced the primary endpoint at 2 years of follow-up. 1.07-1.89) ] follow-up. mADM was a better predictor of these outcomes than MRproADM, apart from death at 90 days, and combined death and heart failure hospitalization at 1 and 2 years, respectively. Human mADM can be reliably measured and predicts MACE events at medium-term follow-up, and confirms the paradigm of risk stratification using MRproADM -a surrogate for the active hormone. The relationship between mADM and MACE appears to be a continuum.
Introduction
The stratification of risk of adverse outcomes after an acute myocardial infarction (AMI) is crucial in the endeavours to curb mortality, and a multiple risk marker strategy is emerging. In addition to the established risk stratification tools such as the Global Registry of Acute Coronary Events (GRACE) score and others, 1 biomarkers such as the natriuretic peptides have now been firmly established as having significant diagnostic and prognostic values for heart failure and in post-AMI patients. 2, 3 Recently, adrenomedullin (ADM) has emerged as a novel peptide with diagnostic and prognostic significance independently of natriuretic peptides in patients who have suffered an AMI, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] patients presenting with acute chest pain, 14, 15 patients with established heart failure, 16, 17 and in patients presenting with acute dyspnoea in emergency settings. 18, 19 Human mature ADM (mADM) is produced from a large peptide precursor molecule (prepro-ADM) which consists of 185 amino acids via a two-staged enzymatic process. Firstly, the precursor is converted into an inactive C-terminally glycine-extended peptide intermediate, which is then subsequently converted into the mature form with 52 amino acids, through enzymatic amidation. 20 The gene encoding for ADM is located within the short arm of chromosome 11. 21 Measurement of total mADM as a biomarker has been previously hampered by its short plasma half-life of 22 AE 1.6 min, 22 the presence of a binding protein called human ADM-binding protein (AMBP-1) identified as complement factor H, 23 and the immediate binding of ADM to the local receptors, which had rendered its accurate measurement difficult to achieve. 23, 24 A possible solution to this problem came from the development of assays to identify midregional pro-ADM (MRproADM), which is a more stable and apparently non-functional fragment of the initial precursor peptide, consisting of 45-92 amino acids. MRproADM is secreted in stoichiometric amounts to mADM and therefore acts as a reliable surrogate of mADM levels. 24 However, conceptually, using MRproADM as a surrogate for mADM has limitations: it does not reflect potential misbalances between the non-functional glycine-extended and the mature ADM,
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and it must be assumed to have different clearing kinetics than mADM.
Previous analytical laboratory methods could only measure free mADM, but reliability of assays was problematic. 23 Earlier studies showed significant associations between free mADM and cardiovascular outcomes in patients with AMI. 7, 9, 10, 25, 26 However, recent studies have shown the prognostic values of MRproADM in this patient group. [4] [5] [6] 11, [13] [14] [15] 27, 28 There are currently no reliable assays for the measurement of total human mADM. We, therefore, undertook this study to determine the prognostic significance of human mADM measured with the novel sandwich immunoassay, using anti-C-terminal and an anti-mid-regional monoclonal antibody, which specifically detects the mADM, but neither the non-functional glycine-extended variant nor the unprocessed pro-hormone, in relation to major adverse cardiovascular events (MACEs) at 1-year follow-up, in ST-elevation myocardial infarction (STEMI) and non-ST-elevation myocardial infarction (NTSEMI) patients. We also compared mADM and MRproADM in relation to MACEs in the same group of patients.
Methods

Study population
The study population of this cohort consisted of 1111 consecutive patients with AMI (STEMI and NSTEMI), admitted to the University Hospitals of Leicester NHS Trust between 2005 and 2008. Written informed consent was obtained from patients, and the study complied with the Declaration of Helsinki and was approved by the local ethics committee. AMI was diagnosed if a patient had a plasma cardiac troponin I level greater than 0.1 ng/ml, with at least one of the following: chest pain lasting for more than 20 min or diagnostic serial ECG changes consisting of new pathological Q-waves or ST-segment and T-wave changes. The Centaur cTnI Ultra Immunoassay (Siemens Healthcare Diagnostics) was used to measure troponin I, which has a coefficient of variation of 10% at 0.03 ng/ml with a 99th percentile of 0.04 ng/ml. Hypertension was defined as a blood pressure measurement of greater than 140/90 mmHg on two or more occasions, or if the patient was on medication for hypertension. Hypercholesterolaemia was defined as total cholesterol of greater than 5.0 mmol/l, or treatment with a statin. Diabetes was defined as random plasma glucose of 11.1 mmol/l, fasting plasma glucose of 7 mmol/l, or a history of diabetes on treatment. Past medical history of ischaemic heart disease [angina or myocardial infarction (MI)], heart failure, and smoking history (current or ex-smoking) was obtained directly from patients or from their medical records. Data on demographics, clinical including treatment, laboratory, and echocardiography were obtained. The estimated glomerular filtration rate (eGFR) was calculated from the simplified formula derived from the Modification of Diet in Renal Disease study. All patients received standard secondary prevention therapy for ischaemic heart disease, and revascularization was at the discretion of the attending physician.
Blood sampling Blood samples were drawn at day 1 to day 5 after admission with AMI. Blood samples were taken after 15 min of bed rest. Venous blood (20 ml) was taken from the antecubital vein into tubes containing EDTA (1 ml/10 ml blood) and aprotinin (500 international units/ml blood). The blood samples were immediately immersed in ice and then centrifuged at 3000 r.p.m. 108C for 15 min. The plasma was aspirated and stored at À808C until assayed in a blinded fashion in a single batch.
Mature adrenomedullin assay
Mature adrenomedullin was detected using a novel research assay provided by Sphingotec GmbH (Hennigsdorf, Germany), as previously described. 29, 30 The ADM assay is a one-step sandwich-coated tube chemiluminescence immunoassay, based on Acridinium NHS-ester labelling for the detection of human ADM in unprocessed, neat plasma. It employs two mouse monoclonal antibodies -one directed against the mid-region (solid phase), the other directed against the C-terminal moiety of ADM (labelled antibody). Polystyrene tubes (Greiner) were coated with the anti-mid-regional antibody (per tube 1.5 mg antibody in 300 ml of 50 mmol/l Tris, 100 mmol/l NaCl, pH 7.8) overnight at 228C. The tubes were then blocked with 10 mmol/l Na-phosphate (pH 6.5) containing 3% Karion FP (Merck) and 0.5% BSA (protease-free) and lyophilized. The anti-C-terminal antibody (1 g/l) was labelled by incubation with MACN-acridinium-NHS (N-hydroxysuccinimide)-ester (1 g/l; InVent GmbH, Hennigsdorf, Germany) in a 1 : 5 molar ratio for 20 min at 228C. The reaction was stopped by addition of 1/5 volume of 50 mmol/l glycine for 10 min at 228C. Labelled antibody was separated from free label by size exclusion chromatography first on a Centri Pure P5 Hydrated gel filtration column (emp Biotech GmbH, Berlin, Germany), followed by a Bio-Silect SEC 400-5 column (Bio-Rad) for HPLC. For the immunoassay, the labelled antibody was diluted into assay buffer [300 mmol/l K-phosphate; 100 mmol/l NaCl; 10 mmol/l Na-EDTA; 5 g/l BSA (protease-free) (Sigma); 1 g/l each of non-specific bovine and mouse IgG; 0.9 g/l Na-azide; (RLU) per 200 ml] were pipetted into the coated tubes. The assay was incubated for 18 h at 48C. Unbound tracer was removed by washing five times with wash solution (1 ml each). Tube-bound chemiluminescence was measured for 1 s by using the LB953 Multi-Tube Luminometer (Berthold Technologies GmbH & Co., KG, Germany). The analytical assay sensitivity was 2 pg/ml. The median ADM concentration of 200 healthy individuals was 20.7 pg/ml; the 99th percentile was 43 pg/ml.
Mid-regional pro-adrenomedullin assay Mid-regional pro-adrenomedullin was detected using a novel commercial assay (BRAHMS AG, Hennigsdorf, Germany), as previously described. 31 Briefly, tubes were coated with a purified sheep polyclonal antibody raised against a peptide representing amino acids 83-94 of prepro-ADM. A purified sheep methylacridinium N-hydroxysuccinimide ester-labelled polyclonal antibody directed against amino acids 68-86 of prepro-ADM was used as a tracer. The immunoassay was performed by incubating 10 ml of samples/standards and 200 ml of tracer in coated tubes for 2 h at room temperature and measuring the bound chemiluminescence using an LB952T luminometer (Berthold, Bad Wildbad, Germany). The lower detection limit of the assay is 0.08 nmol/l. The intra-assay (inter-assay) coefficients of variation at 0.5 and 5 nmol/l were 3% (8.5%) and 3.5% (6.5%), respectively.
N-terminal pro-B-type natriuretic peptide assay
Plasma N-terminal pro-B-type natriuretic peptide (NTproBNP) assay was measured using a non-competitive immunoluminometric assay, as previously published. 3 
Endpoints
The primary endpoint was MACEs at 30 days, 90 days, 1 year, and 2 years of follow-up, which was a composite of all-cause mortality, myocardial re-infarction, and hospitalization for heart failure. The secondary endpoints were: death, hospitalization for heart failure, myocardial re-infarction, a combination of death and hospitalization for heart failure, a combination of death and myocardial re-infarction, and a combination of MI and hospitalization for heart failure. Deaths were validated by reviewing the hospital record management systems and the Office of National Statistics Registry. Hospitalization for heart failure was defined as a hospital admission for which heart failure was the primary reason, requiring treatment with high-dose diuretics, inotropes, or intravenous nitrate with echocardiographic evidence of heart failure. New MI was defined as for the initial AMI. New MI and heart failure endpoints were ascertained using computerized hospital patients records for University Hospitals of Leicester, and were validated by contacting each patient.
Statistical analyses
Statistical analyses were done using STATA version 11. Quartiles of mADM were created. Hypothesis testing was done using analysis of variance (ANOVA) for trend across quartiles of mADM for normally distributed continuous variables, Kruskal-Wallis tests for skewed variables, and chi-square test for trend for categorical variables. Independent correlates of mADM were estimated using the generalized linear model. Univariate and multivariate hazard ratios for the predictive impact of baseline mADM on endpoints were estimated by the Cox proportional-hazard model. The likelihood ratio chi-square test was used to test for statistical significance of each variable in the Cox regression model. Curves of Kaplan-Meier MACE-free and survival estimates were obtained and the log-rank test was used to compare MACE-free and survival estimates across quartiles of mADM. Table 1 shows patients characteristics across quartiles of mADM. The cohort consisted of 519 STEMI patients (46.7%). Men had lower levels of mADM levels compared with women. There was a significant positive trend for age, past medical history of ischaemic heart disease, hypertension, diabetes mellitus, and smoking history across tertiles of mADM, but not for history of hyperlipidaemia and chronic obstructive airway disease. The same pattern was seen for MRproADM.
Results
Patients characteristics
Daily variation of human mature adrenomedullin and relationship with endpoint (major adverse cardiovascular event at 1 year) Daily samples of mADM were collected for 5 days. As shown in Fig. 1 , mADM level increased up to day 2 (P < 0.0005), and then remained elevated on repeated-measures analysis with Bonferroni correction, with MACE at 1 year as a factor. ADM levels were higher in patients with MACE compared with those without MACE (P < 0.0005). There was no interaction between MACE and the time of sampling. Also, there was no significant effect of daily variation of mADM on the outcome measures.
Correlates of mature adrenomedullin and mid-regional pro-adrenomedullin There was a strong correlation between mADM and MRproADM, as shown in Fig. 2 , with coefficient of 0.63 (P < 0.001). Using the generalized linear model, independent multivariate correlates of mADM were NT-proBNP (P ¼ 0.001), eGFR (P < 0.001), past medical history of diabetes mellitus on admission (P ¼ 0.039), and history of heart failure (P ¼ 0.014). The relationship between eGFR and mADM was inverse and appeared very strong, whereas mADM was positively correlated to the rest of the above mentioned covariates. Independent correlates of MRproADM were NT-proBNP (P < 0.001), mADM (P < 0.001), eGFR (P < 0.001), and past medical history of diabetes mellitus (P ¼ 0.007).
Adrenomedullin in acute myocardial infarction Yuyun et al. 45 Table 1 Characteristics of patients according to admission levels of human mature adrenomedullin and mid-regional pro-adrenomedullin variables mADM (admission tertiles) (pg/ml) Table  3 . Overall, the results indicate that mADM was a better predictor of primary and secondary endpoints than MRproADM, apart from death at 90 days, and combined death and heart failure hospitalization at 1 and 2 years, respectively, in which case MRproADM was a better predictor. This was confirmed by added value analysis of nested regression models, and the reason appears to be that MRproADM is correlated to NT-proBNP, whereas mADM is not (data not shown).
Taking ADM as a categorical variable, hazard ratio (95% CIs) for 2-year MACE in the upper tertile of mADM compared with the lower two tertiles was 1. Human mature adrenomedullin and survival Figures 3 and 4 show Kaplan-Meier estimates for MACE-free and survival, respectively, at 2 years of follow-up. There was a significant trend of these outcomes across tertiles of mADM. For MRproADM, a significant decrease in MACE-free and survival estimates was observed in patients at the upper tertile, as evident by the log-rank test.
Receiver operator characteristic curve
The area under the curve (AUC) and 95% CIs for 2-year MACE was 0.63 (0.59-0.66) for mADM, compared with 0.69 (0.66-0.73) for MRproADM and 0.69 (0.65-0.73) for NT-proBNP (P ¼ 0.0002). The AUC for 2-year all-cause mortality was 0.64 (0.60-0.69) for mADM and 0.76 (0.71-0.80) for NT-proBNP (P ¼ 0.0004). Although NT-proBNP had a better AUC, mADM was a more significant predictor of outcomes in multivariate Cox regression analysis.
Discussion
We have shown that using the novel sandwich immunoassay, using anti-C-terminal and an anti-mid-regional MRproADM (nmol/l)
Scatter plot mADM versus MRproADM
Scatter plot of human mature adrenomedullin (mADM) and mid-regional pro-adrenomedullin (MRproADM).
monoclonal antibody, total mature mADM can be reliably measured and that levels are fairly stable over 5 days of serial measurements. Our study showed that mADM is predictive of MACEs at 90 days, 1 year, and 2 years, as well as predictive of death at 1 and 2 years. This study also depicted that MRproADM is a significant predictor of death at 90 days, and 1 and 2 years of followup. We observed that MRproADM has similar predictive effects with regard to MACEs and death as mADM, although when introduced into the same stepwise multivariate prediction model as mADM, its significance tended to fade out in favour of mADM. Our findings are significant as they confirm that the prognostic effects of mADM in AMI patients are similar to MRproADM, which has been established as its stable and reliable surrogate. 24 However, we observed that the relationship between mADM and MACEs was a continuum, whereas there appears to be a threshold effect in our study with MRproADM, which has been observed in other studies. 5, 15 To the best of our knowledge, this is the first study to look at the active mature peptide and its inactive propeptide surrogate in the same study population in relation to MACEs. Our findings are significant as they confirm that the prognostic effects of mADM in AMI Adrenomedullin in acute myocardial infarction Yuyun et al. 47 Table 3 Cox regression of human mature adrenomedullin and mid-regional pro-adrenomedullin for various outcomes Above are hazard ratios (95% confidence intervals) derived from back stepwise Cox regression analysis. HF, heart failure; MACE, major adverse cardiovascular events; mADM, mature human adrenomedullin; MI, myocardial infarction; MRproADM, mid-regional pro-adrenomedullin; NS, not significant and rejected out of the final multivariate regression model; N/B: mADM and MRproADM were introduced separately into the models. Introduction of both variables into various predictive models of the above outcomes invariably excluded MRproADM from the model, leaving mADM as a better predictor for most of the outcomes, apart from death at 90 days and combined death and heart failure hospitalization at 1 and 2 years, in which case MRproADM was a better predictor. Above multivariate analyses were adjusted for age, sex, N-terminal pro-Btype natriuretic peptide (NT-proBNP), hyperlipidaemia, ischaemic heart disease history, smoking, Killip class, GRACE score on admission, SBP, serum glucose, eGFR, left ventricular ejection fraction, class of myocardial infarction (STEMI vs. NSTEMI), and discharge medications. Above are hazard ratios (95% confidence intervals) with multivariate values derived from back stepwise Cox regression analysis. ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate in ml/min/1.73 m 2 surface area; glucose, log to base of serum glucose; GRACE, Global Registry of Acute Coronary Events; IHD, ischaemic heart disease; mADM, mature human adrenomedullin; NS, not significant and rejected out of the final multivariate regression model; NSTEMI, non-ST-elevation myocardial infarction; NT-proBNP, N-terminal pro-B-type natriuretic peptide; STEMI, ST-elevation myocardial infarction.
a One SD increased in variable. 
MACE-free Kaplan-Meier estimates across mADM tertiles
Major adverse cardiovascular event (MACE)-free Kaplan-Meier estimates across tertiles of adenomedullin. Above are MACE-free Kaplan-Meier estimates at 2 years for human mature adrenomedullin (mADM), log-rank test 29.84 (P < 0.001); and mid-regional pro-adrenomedullin (MRproADM), log-rank 123.98 (P < 0.001). Kaplan-Meier survival estimates across mADM tertiles
Kaplan-Meier survival estimates across tertiles of adrenomedullin. Above are Kaplan-Meier survival estimates at 2 years for human mature adrenomedullin(mADM), log-rank 18.64 (P < 0.001); and mid-regional pro-adrenomedullin (MRproADM), log-rank 118.49 (P < 0.001).
patients are similar to MRproADM which has been established as its stable and reliable surrogate as observed by the LAMP Study and the LAMP Study II, 5, 8 and others. 4, 6, [11] [12] [13] Adrenomedullin is a known as an independent predictor of future MACEs in coronary disease. It significantly predicts fatal and non-fatal cardiovascular events and all-cause mortality in patients with stable angina, 4, 27, 28, 32 patients with acute coronary syndromes, [4] [5] [6] [7] [8] [9] [10] [11] 13 and patients presenting with acute chest pain.
14,15 Our findings corroborate the above observations and help to enhance the importance of ADM as a prognostic marker in acute coronary syndromes, whether as the mADM or its surrogate MRproADM, independently of other established risk markers such as the GRACE score and the natriuretic peptides. Initial studies used free ADM to relate to cardiovascular outcomes, 7,9,10 whereas more recent studies have used the surrogate MRproADM to study this relationship. [4] [5] [6] 8, 14, 15, 27, 33 Abundant evidence has accrued, suggesting the important role ADM might be playing in cardiovascular disease. The ADM plasma levels are increased in atherosclerosis in coronary and peripheral circulation, and there is augmented expression with severity of plaque formation/stenosis and degree of ischaemic heart disease syndromes, for example, less expression in patients with stable angina compared with those with unstable angina. 34 Adrenomedullin level is significantly increased in AMI, 25 and it correlates with the severity of AMI. 26 Intravenous ADM infusion to AMI patients significantly reduces the infarct size and prospectively reduces the regional wall motion abnormality on cardiac MRI. 35 An expanding number of studies have shown diagnostic and prognostic significance of ADM in heart failure patients. Initial cross-sectional studies demonstrated that ADM levels were significantly raised in patients with established heart failure compared with controls. 36 ADM is proportionally elevated in cardiac failure to the severity of the disease, assessed by NYHA, and to the degree of left ventricular impairment. 6, 16 ADM also has diagnostic value alongside the natriuretic peptides in acute dyspnoea and in chronic heart failure, 16, 18, 19, 37 and diastolic dysfunction. 38 In post-AMI patients with new heart failure, 6 patients with established heart failure, 16, 17 and in patients presenting with acute dyspnoea in emergency settings, 18, 19, 37, 39 MRproADM has been shown to have independent prognostic significance for major adverse cardiovascular outcomes. It is also predictive of adverse outcomes in community patients with symptoms of heart failure, 40 although one large population study did not show its predictive utility for incident heart failure. 41 The receptors of ADM are a complex of receptor activitymodifying proteins (RAMPs) and calcitonin receptor-like receptors (CRLRs). 42 The mechanisms of action of ADM are thought so far to be through the generation of nitric oxide via nitric oxide-cyclic guanine monophosphate pathway or through increased intracellular cyclic adenosine monophosphate, which activates protein kinase A, which in turn activates nitric oxide synthase or through phosphatidylinositol kinase-3 activation and Akt phosphorylation, resulting in enhanced stimulation of endothelial nitric oxide synthase.
21,34
Limitations
The study findings are from a single centre and will need to be replicated in other patient populations. Only five daily measures of mADM were taken after initial presentation, and we cannot account for the variability of these peptides during the follow-up period. Measurements of peptides were carried out on samples that were frozen, but lack of differential treatment of samples should uphold the internal validity of our findings.
Conclusions
(1) Human mADM can be reliably measured, and levels are stable for up to 5 days after AMI. (2) Mature ADM is an independent predictor of MACEs at short and medium-term follow-up. The relationship between mADM and MACEs appears to be a continuum.
Clinical perspectives
(1) Reliable measurement of human mADM has been difficult. (2) Mid-regional pro-ADM has been a reliable surrogate of mADM. (3) Mid-regional pro-ADM predicts adverse outcomes in MI patients. (4) We reliably measured mature human mADM using the novel sandwich immunoassay and showed that mADM is predictive of MACEs in STEMI and NSTEMI patients. (5) Both mADM and MRproADM are predictive of outcomes, confirming the surrogacy of MRproADM for mADM in relation to outcome, but mADM is a better predictor of outcomes in this study than MRproADM. (6) This confirms the paradigm of risk stratification using MRproADM, a surrogate for the active hormone.
